Skip to main content
. 2022 Sep 28;2(9):1075–1088. doi: 10.1158/2767-9764.CRC-22-0053

FIGURE 1.

FIGURE 1

Navtemadlin inhibits murine cell growth in a p53-dependent manner. A–E, Cell growth, measured as % confluence over time, of B16-F10 p53+/+ and p53−/− mouse melanoma cells, YUMM 1.7 mouse melanoma cells, CT26.WT mouse colon carcinoma cells, and NIH/3T3 mouse fibroblast cells treated with indicated concentrations of Navtemadlin or vehicle control was monitored for 96 hours (IncuCyte S3 system). F, Representative plots showing flow cytometry analyses of cell-cycle measuring incorporation of EdU into newly synthesized DNA after 72 hours treatment with 1.5 μmol/L Navtemadlin. DNA was stained with FxCycle. The gates were based on FMO controls. G and H, Cell-cycle phases of B16-F10 p53+/+ and p53−/− cells 24, 48, and 72 hours after treatment with 1.5 μmol/L Navtemadlin based on EdU incorporation in proliferating cells. The data are representative of at least two experiments performed with triplicates. Mean ± SD. *, P <0.05; ****, P < 0.0001. One-way ANOVA.